Evidence map›Paper›PMID 42062689›Full record

ArticleDermatology and therapy2026

Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO

Adilson DaCosta, Cláudio de Lélis Filgueiras de Souza, Renan Minotto, Selam Shah, Olga Moshkovich, James P Stansbury, Siu-Long Yao, ViSENPsO Study Group

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adilson DaCosta *Instituto de Assistência Médica ao Servidor Público Estadual, Rua Pedro de Toledo, 1800-Vila Clementino, São Paulo, Brazil. adilson_costa@hotmail.com.ORCID http://orcid.org/0000-0003-0873-6840
Cláudio de Lélis Filgueiras de SouzaUniversidade José do Rosário Vellano (UNIFENAS), Alfenas, Brazil.
Renan MinottoDepartment of Dermatology, Hospital Santa Casa de Porto Alegre, Porto Alegre, Brazil.
Selam ShahICON Plc, Boston, MA, USA.
Olga MoshkovichICON Plc, Raleigh, NC, USA.
James P Stansbury *ICON Plc, Blue Bell, PA, USA.
Siu-Long Yao *Sun Pharma Advanced Research Company Limited, Princeton, NJ, USA.
ViSENPsO Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA reliable, well-defined measure of fingernail psoriasis severity for clinical trials is an unmet need. The objective of this study was to develop and validate the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO), an illustrated 5-point tool for assessing nail psoriasis severity.

methodsA global panel of dermatologists participated in concept elicitation (CE) interviews exploring experiences with nail psoriasis, severity markers, and biologic treatment. Participants sorted and ranked histopathology-verified photographs to refine severity categories. Follow-up cognitive interviews assessed the scale's usability and content validity, alongside a preliminary test of interrater reliability (IRR). Dermatologists' assessments were analyzed using thematic analysis to generate qualitative insights.

resultsSixteen dermatologists participated in CE and five in cognitive interviews. Consensus analysis showed strong alignment among high task competence (expertise ratings [r

conclusionViSENPsO is a validated, visually guided tool for assessing standardized nail psoriasis severity. Preliminary interrater agreement was observed; comprehensive psychometric validation, including full IRR and sensitivity to change, is ongoing.

Indexed as

Clinical researchGeneral dermatologyMedical dermatologyNail psoriasisScaleValidationViSENPsO

Identifiers

PMID42062689
PMCPMC13237405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.